Cancer Research Audrey Hepburn Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitehall, V. L. J.
Right arrow Articles by Jass, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitehall, V. L. J.
Right arrow Articles by Jass, J. R.
[Cancer Research 62, 6011-6014, November 1, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Morphological and Molecular Heterogeneity within Nonmicrosatellite Instability-High Colorectal Cancer1

Vicki L. J. Whitehall2, Coral V. A. Wynter, Michael D. Walsh, Lisa A. Simms, David Purdie, Nirmala Pandeya, Joanne Young, Stephen J. Meltzer, Barbara A. Leggett and Jeremy R. Jass

Conjoint Gastroenterology Laboratory, Clinical Research Centre, Royal Brisbane Hospital Research Foundation, Queensland 4029, Australia [V. L. J. W., C. V. A. W., M. D. W., L. A. S., J. Y., B. A. L.]; Division of Population Studies and Human Genetics, Queensland Institute of Medical Research, Queensland, Australia 4029 [D. P., N. P.]; University of Maryland, Baltimore, Baltimore, Maryland 21201 [S. J. M.]; and Department of Pathology, University of Queensland, Brisbane, Queensland, Australia 4006 [J. R. J.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Colorectal cancer (CRC) has traditionally been classified into two groups: microsatellite stable/low-level instability (MSS/MSI-L) and high-level MSI (MSI-H) groups on the basis of multiple molecular and clinicopathologic criteria. Using methylated in tumor (MINT) markers 1, 2, 12, and 31, we stratified 77 primary CRCs into three groups: MINT++ (>2), MINT+ (1–2), and MINT- (0 markers methylated). The MSS/MSI-L/MINT++ group was indistinguishable from the MSI-H/MINT++ group with respect to methylation of p16INK4a, p14ARF, and RIZ1, and multiple morphological features. The only significant difference between MSI-H and non-MSI-H MINT++ cancers was the higher frequency of K-ras mutation (P < 0.004) and lower frequency of hMLH1 methylation (P < 0.001) in the latter. These data demonstrate that the separation of CRC into two nonoverlapping groups (MSI-H versus MSS/MSI-L) is a misleading oversimplification.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
A series of CRCs3 may be perceived as a biological continuum within which there may be discontinuities as revealed by particular tests. A test may form the basis of a classification if it generates groups that are distinguished by clinical, pathological, or molecular features. Stratification on the basis of testing for DNA MSI identifies a MSI-H subset with well-established clinical and pathological correlates (1 , 2) . Silencing of the DNA mismatch repair gene hMLH1 by methylation of a CpG island within its promoter region is the usual mechanism for generating sporadic MSI-H CRC (3, 4, 5) . The fact that no single feature is the exclusive property of MSI-H CRC indicates that the disease is a continuum rather than an aggregation of separate disease types.

Testing CRCs with DNA microsatellite markers identifies a low-level group (MSI-L) that is not as well defined as the MSI-H subset. Most CRCs reveal MSI-L to some degree when tested with a large panel of microsatellite markers, but the distribution of instability is nonrandom. At one end of the spectrum is an excess of "super-stable" cancers, whereas at the other end there is an excess of "true MSI-L" cancers with between 10 and 25% of markers showing instability (6) . One explanation for the variation in MSI-L levels is somatic alteration of genes having a relatively subtle influence on the efficiency of DNA mismatch repair. In keeping with this suggestion, methylation and loss of expression of the DNA repair gene MGMT is associated with MSI-L status (7) .

An alternative but related approach to classifying CRC is through testing for the presence of methylation of CpG islands. Sporadic MSI-H cancers with methylation of hMLH1 show the CIMP in which multiple CpG-rich genes and MINT loci are methylated (8) . However, CIMP-positive cancers include some that are non-MSI-H (9) . Because methylation is a specific mechanism for gene silencing, whereas MSI is merely an epiphenomenon serving as a biomarker for DNA mismatch repair deficiency, it might be supposed that methylator status would serve as the more valid basis for tumor classification. Classification on the basis of MSI testing might result in the artificial splitting of a group defined on the basis of CIMP status. To explore this hypothesis we have examined the distribution of multiple variables across CRCs stratified by both MSI and CIMP status. The study shows that cancers with multiple MSI-H-related features occur outside the MSI-H group, a finding that may be relevant to theories of tumorigenesis.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
The material was derived from a prospectively collected, hospital-based frozen tumor bank comprising 879 CRC specimens, and classified as MSI-H, MSI-L, and MSS using at least six DNA microsatellite markers (10 , 11) . Instability in >=40% of markers was taken as the breakpoint distinguishing MSI-H from MSI-L cancers. Specimens comprising 16 MSI-H, 38 MSI-L, and 23 MSS cancers were included in the study on the basis of prior molecular characterization with regard to microsatellite status, K-ras mutation, methylation of MGMT, and immunohistochemical evaluation of MGMT and hMLH1 expression, as well as availability of DNA for additional methylation assays (7 , 12) . The MSS cases were a randomly selected subset of this dominant group.

Methylation-specific PCR was used to test for methylation as has been described previously for p16INK4a (13) , p14ARF (14) , MGMT (15) , and RIZ1 (16) .

COBRA for hMLH1 methylation (17) was modified to include nested primers for increased sensitivity. The nested sense primer was 5'-GATTTAGTAATTTATAGAGT-3' and antisense was 5'-AATACCTTCAACCAATCAC-3'. The primary product was amplified in a total volume of 25 µl containing 2.5 µl bisulfite-modified DNA, 1x PCR buffer (Applied Biosystems), 0.2 mM deoxynucleoside triphosphate, 1.3 mM Mg2+, 4 µM of each primer, and 0.5 units Red Hot Taq (Applied Biosystems). One µl of the primary product was reamplified in a total volume of 50 µl using the same reagent concentrations. Fifteen µl of the nested PCR product was digested with 0.8 units RsaI at 37°C overnight. Digested samples were analyzed on 10% polyacrylamide gels and visualized with ethidium bromide. MINTs 1, 2, 12, and 31 were assayed by COBRA (Fig. 1)Citation .4



View larger version (38K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Methylation analysis by COBRA for hMLH1, MINT1, and MINT12, and by methylation-specific PCR for MGMT, p16INK4a, and p14ARF. Histology for this case is in Fig. 2Citation .

 
Morphological features were scored without knowledge of either MSI or methylator status: (1) grade (poor or other); (2) cytoplasm (eosinophilic or basophilic); (3) morphological heterogeneity with respect to either tumor type or grade of tumor differentiation (absent or present); (4) tumor infiltrating (intraepithelial) lymphocytes (absent or present); (5) invasion (expanding or infiltrating); (6) nuclear chromatin pattern (condensed or vesicular); (7) nuclear shape (round or ovoid); (8) nucleolus (large or small); (9) extracellular mucin (absent or present); (10) solid or medullary pattern (absent or present); (11) goblet cells (absent or present); and (12) epithelial serration (absent or present).

Cancers were grouped as MINT++ (3–4 markers methylated), MINT++ (1–2 markers methylated), and MINT-. All 16 of the MSI-H cancers were MINT++ (group A, n = 16). Non-MINT++/MSI-H cancers may arise through germ line or somatic mutation of a DNA mismatch repair gene. There were 6 MSI-H cancers that showed little or no methylation of MINT loci. These cancers were excluded from this study on the basis that they may have been derived from patients with hereditary nonpolyposis colorectal carcinoma or represent examples of somatic mutation of hMLH1. The non-MSI-H cancers were grouped as B (MINT++; n = 8), C (MINT++; n = 29), and D (MINT-; n = 24).

Morphological and genotypic characteristics of tumors were compared across levels of methylation and MSI using Pearson’s {chi}2 test for association and Fisher’s Exact test (for rare features). As the morphological characteristics of tumors are related, we also conducted multivariate analysis to determine factors that were independently associated with methylation. In particular, anatomical location, tumor heterogeneity, presence of tumor infiltrating lymphocytes, invasion, and extracellular mucin were interrelated, so were adjusted for in all of the analyses. When comparing the four methylation/MSI groups, multinomial logistic regression was used (18) , and when comparing two methylation groups, binary logistic regression was conducted. All of the analyses were performed using SAS for Windows release 8.2. A P < 0.05 was used to determine statistical significance.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Groups A and B (MINT++) were combined and compared with group C plus D (MINT++/-) with respect to morphological features. Crudely, features significantly associated with MINT++ cancers were: tumor heterogeneity (P < 0.001), tumor-infiltrating lymphocytes (P = 0.004), round nuclei (P = 0.015), vesicular nuclei (P = 0.007), prominent nucleoli (P = 0.012), extracellular mucin (P < 0.001), and proximal location (P < 0.001). After multivariate analyses, the only features to retain a significant association with MINT++ cancers were extracellular mucin (P = 0.001) and proximal location (P = 0.05). Group A and B cancers differed from each other only with respect to tumor heterogeneity (P = 0.04). Additionally group B cancers were more likely to show diffuse infiltration (P = 0.03). There were no differences between group A and group B cancers with respect to methylation of p16INK4a, p14ARF, or RIZ1, but K-ras mutation was associated with group B cancers (P = 0.004), and more group B cancers showed MGMT methylation, although the difference was not significant (P = 0.12). Methylation of hMLH1 occurred in all of the group A cancers and in no group B cancers (P < 0.001). There was full immunohistochemical concordance.

After adjusting for confounding factors, group B cancers differed from group C cancers in showing significantly more cases with p16INK4a (P = 0.03) and RIZ1 (P < 0.02) methylation, and included more cancers with extracellular mucin (P = 0.05). There were more group B cancers with methylation of p14ARF, although this did not reach significance (P = 0.09). Differences between group B and group D cancers were in a similar direction with respect to methylation, although the findings for p16INK4a (P = 0.09), p14ARF (P = 0.06), and RIZ1 (P = 0.1) fell short of significance (Table 1)Citation . The distribution of specific MINT methylation appeared to be nonrandom between the four groups. MINT1 methylation was more frequent in group A than group B (P = 0.02), whereas MINT31 was more frequently methylated in group B then group A, although the difference was not significant (P = 0.14). There was no difference in MINT1 methylation between group B and group C (P = 0.2; see Table 1Citation for crude and adjusted Ps across the four groups).


View this table:
[in this window]
[in a new window]

  		Table 1 Distribution of molecular variables in groups A–D (with percentages in brackets)

 
A solid or medullary architecture and an expanding growth pattern are associated with MSI-H cancers. Although these features were not significantly more frequent in group A and B cancers in this study, they were added to heterogeneity, lymphocytes, nuclear shape, chromatin, nucleoli, and mucin to give an overall morphology score (maximum 8). Fifteen of 16 group A cancers scored 5 or more. Four group B (50%), 8 group C (28%), and 4 group D (17%) cancers scored >=5. Among the 16 non-MSI-H cancers with an MSI-H morphology score of >=5, 12 showed methylation of target genes other than hMLH1. The frequency of methylation of MGMT, p16INK4a, p14ARF, and RIZ1 in these cases was 56, 19, 31, and 6%, respectively. The 16 cases showing morphological mimicry of sporadic MSI-H cancer presented at a mean age of 72 years, 8 (50%) occurred in the proximal colon, 9 subjects (56%) were female, and 9 (56%) cancers were MSI-L. Figs. 1Citation and 2Citation illustrate an MSS, group B cancer showing morphological and molecular mimicry of MSI-H cancers.



View larger version (126K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Section of an MSS/MINT++ cancer (Group B). There was methylation of p16INK4a, p14ARF, and MGMT, but not hMLH1 (see Fig. 1Citation ). The cancer shows a medullary or solid pattern, and is infiltrated by lymphocytes (A). Round, vesicular nuclei with large nucleoli are seen at high magnification (B). Immunohistochemistry revealed loss of expression of MGMT (C), whereas hMLH1 expression was retained (D).

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
CRCs may be considered as a continuum in which particular tests such as MSI and CIMP status reveal discontinuities. Features additional to MSI and CIMP status that were tested in this study included 12 morphological variables, methylation of hMLH1, p16INK4a, p14ARF, RIZ1, and MGMT, and K-ras mutation. There was a decreasing gradient of MSI-H-associated morphological and molecular features among non-MSI-H cancers stratified as MINT++ (group B), MINT++ (group C), and MINT- (group D; Table 1Citation ). Group B cancers showed few morphological or molecular differences from group A cancers. Whereas none showed hMLH1 methylation, 7 of the 8 were MSI-L. Even the single MSS MINT++ cancer revealed marked morphological (Fig. 2)Citation and molecular (methylation of p16INK4a, p14ARF, and MGMT) overlap with MSI-H cancers. The findings suggest that MSI-H morphology, and p16INK4a, p14ARF, and MGMT methylation are not dependent on MSI status. It is more likely that the shared features among MSI-H and subsets of non-MSI-H cancers are explained by a common pathway of tumorigenesis in which methylation plays a key role in gene silencing.

A distinguishing feature of group A and group B cancers (apart from methylation of hMLH1) was the high frequency of K-ras mutation within the latter. A low frequency of K-ras mutation in sporadic MSI-H cancer is described in the literature (11 , 19 , 20) . Within the non-MSI-H group there is evidence that the highest frequency of K-ras mutation occurs within CIMP-positive CRCs (9 , 21) , MSI-L CRCs (11 , 22 , 23) , or both. The highest frequency of K-ras mutation (90%) is recorded in non-MSI-H CIMP-positive cancers (9) , whereas the lowest frequency is recorded in a super-stable group of cancers (6) . The declining gradient of K-ras mutation in groups B (50%), C (45%), and D (33%) in the present study is consistent with the preceding findings. Methylation of MGMT could explain the observations, at least in part. Silencing of this DNA repair gene by methylation of its promoter region has been associated with G to A transition mutation in K-ras (15) and with MSI-L status in CRC (7) .

The serrated pathway, implying an origin within hyperplastic polyps, admixed polyps, or serrated adenomas, would serve as the basis for the preceding observations. There is evidence that methylation is an important mechanism for gene silencing in this pathway. Serrated polyps probably arise within nondysplastic microscopic lesions called aberrant crypt foci. Both aberrant crypt foci and serrated polyps show molecular heterogeneity with subsets characterized by methylation of hMLH1 (24 , 25) and/or MGMT (7 , 24) , and/or K-ras mutation (24) . An association between MGMT methylation and K-ras mutation has also been observed in serrated adenomas (26) . It is also relevant that the cytological and architectural features of CIMP+ cancers are also shared by serrated polyps (12) . The likeness is functional as well as morphological, extending to the up-regulation of gastric (MUC5AC) and intestinal (MUC2) secretory mucin in hyperplastic polyps, serrated adenomas, and sporadic MSI-H CRC (27) . In this study, glandular serration occurred least frequently in nonmethylated cancers, although the adjusted P fell just short of significance (Table 1)Citation .

Methylation of MGMT showed no association with MINT status. It is possible that cancers in different molecular groups may share a common origin, for example driven by silencing of MGMT, but then diverge at an early stage into different tumorigenic pathways. The implication of this suggestion is that a significant proportion of CRCs may originate in microscopic lesions that are nonadenomatous and are initiated by mechanisms other than APC mutation, for example methylation of DNA repair genes and/or K-ras mutation. APC mutation may occur in this alternative pathway but not necessarily as the first event. In summary, a subset of non-MSI-H cancers mimics MSI-H cancers morphologically and with respect to frequent methylation of target genes other than hMLH1. Methylation of these genes may result in a selective growth advantage, and in the case of MGMT the conferred advantage may be such that methylation of this DNA repair gene occurs in the absence of extensive MINT methylation.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by National Cancer Institute Grant 1-U01-CA74778 (Collaborative Family Registry for Colorectal Cancer Family Studies); the National Health and Medical Research Council of Australia; the Walter Paulsen Memorial Tumor Bank; and NIH Grants CA77057, CA85069, and CA95323. V. L. J. W. was supported by the Gastroenterology Society of Australia Biomedical Research Scholarship and the Paul Mackay Bolton Research Scholarship. Back

2 To whom requests for reprints should be addressed, at Conjoint Gastroenterology Laboratory, Bancroft Centre, Herston Road, Queensland 4029, Australia. Phone: 617-3362-0491; Fax: 617-3362-0108; E-mail: vickiWh{at}qimr.edu.au Back

3 The abbreviations used are: CRC, colorectal cancer; MSS, microsatellite stable; MSI-L, low-level microsatellite instability; MSI-H, high-level microsatellite instability; MGMT, O-6-methylguanine-DNA- methyltransferase; CIMP, CpG island methylator phenotype; MINT, methylated in tumor; COBRA, combined bisulfite restriction analysis. Back

4 Internet address for detailed protocols: http://www.med.jhu.edu/methylation/primers.htm. Back

Received 3/12/02. Accepted 9/18/02.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Kim H., Jen J., Vogelstein B., Hamilton S. R. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am. J. Pathol., 145: 148-156, 1994.[Abstract]
  2. Jass J. R., Do K. A., Simms L. A., Iino H., Wynter C., Pillay S. P., Searle J., Radford-Smith G., Young J., Leggett B. A. Morphology of sporadic colorectal cancer with DNA replication errors. Gut, 42: 673-679, 1998.[Abstract/Free Full Text]
  3. Kane M. F., Loda M., Gaida G. M., Lipman J., Mishra R., Goldman H., Jessup J. M., Kolodner R. D. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res., 57: 808-811, 1997.[Abstract/Free Full Text]
  4. Herman J., Umar A., Polyak K., Graff J., Ahuja N., Issa J., Markowitz S., Willson J., Hamilton S., Kinzler K., Kane M., Kolodner R., Vogelstein B., Kunkel T., Baylin S. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.[Abstract/Free Full Text]
  5. Cunningham J. M., Christensen E. R., Tester D. J., Kim C., Roche P. C., Burgart L. J., Thibodeau S. N. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res., 58: 3455-3460, 1998.[Abstract/Free Full Text]
  6. Halford S., Sasieni P., Rowan A., Wasan H., Bodmer W. F., Talbot I., Hawkins N., Ward R., Tomlinson I. Low-level microsatellite instability occurs in most colorectal cancers and is a nonrandomly distributed quantitative trait. Cancer Res., 62: 53-57, 2002.[Abstract/Free Full Text]
  7. Whitehall V. L. J., Walsh M. D., Young J., Leggett B. A., Jass J. R. Methylation of 0–6-methylguanine DNA methyltransferase characterises a subset of colorectal cancer with low level DNA microsatellite instability. Cancer Res., 61: 827-830, 2001.[Abstract/Free Full Text]
  8. Toyota M., Ahuja N., Ohe-Toyota M., Herman J. G., Baylin S. B., Issa J. J. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA, 96: 8681-8686, 1999.[Abstract/Free Full Text]
  9. Toyota M., Ohe-Toyota M., Ahuja N., Issa J. J. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc. Natl. Acad. Sci. USA, 97: 710-715, 2000.[Abstract/Free Full Text]
  10. Boland C. R., Thibodeau S. N., Hamilton S. R., Sidransky D., Eshleman J. R., Burt R. W., Meltzer S. J., Rodriguez-Bigas M. A., Fodde R., Ranzani G. N., Srivastava S. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res., 58: 5248-5257, 1998.[Abstract/Free Full Text]
  11. Jass J. R., Biden K. G., Cummings M., Simms L. A., Walsh M., Schoch E., Meltzer S. J., Wright C., Searle J., Young J., Leggett B. A. Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J. Clin. Pathol., 52: 455-460, 1999.[Abstract]
  12. Young J., Simms L. A., Biden K. G., Wynter C. V. A., Whitehall V. L. J., Karamatic R., George J., Goldblatt J., Walpole I., Robin S., Borten M. M., Stitz R., Searle J., McKeone D., Fraser L., Purdie D. R., Podger K., Price R., Buttenshaw R., Walsh M. D., Barker M. B., Leggett B. A., Jass J. R. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings. Am. J. Pathol., 159: 2107-2116, 2001.[Abstract/Free Full Text]
  13. Herman J. G., Graff J. R., Myohanen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.[Abstract/Free Full Text]
  14. Esteller M., Tortola S., Toyota M., Capella G., Peinado M. A., Baylin S. B., Herman J. G. Hypermethylation-associated inactivation of p14ARF is independent of p16INK4A methylation and p53 mutational status. Cancer Res., 60: 129-133, 2000.[Abstract/Free Full Text]
  15. Esteller M., Toyota M., Sanchez-Cespedes M., Capella G., Peinado M. A., Watkins D. N., Issa J. J., Sidransky D., Baylin S. B., Herman J. G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res., 60: 2368-2371, 2000.[Abstract/Free Full Text]
  16. Du Y., Carling T., Fang W., Piao Z., Jin-Chuan S., Huang S. Hypermethylation in human cancer of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res., 61: 8094-8099, 2001.[Abstract/Free Full Text]
  17. Suzuki H., Itoh F., Toyota M., Kikuchi T., Kakiuchi H., Hinoda Y., Imai K. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int. J. Cancer, 83: 309-313, 1999.[Medline]
  18. Hosmer D. W., Lemeshow S. . Applied, Ed. 2 260-287, John Wiley and Sons New York 2002.
  19. Gebert J., Sun M., Ridder R., Hinz U., Lehnert T., Moller P., Schackert H. K., Herfarth C., von Knebel D. B. Molecular profiling of sporadic colorectal tumors by microsatellite analysis. Int. J. Oncol., 16: 169-179, 2000.[Medline]
  20. Samowitz W. S., Holden J. A., Curtin K., Edwards S. L., Walker A. R., Lin H. A., Robertson M. A., Nichols M. F., Gruenthal K. M., Lynch B. J., Leppert M. F., Slattery M. L. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am. J. Pathol., 158: 1517-1524, 2001.[Abstract/Free Full Text]
  21. Hawkins N., Norrie M., Cheong K., Mokany E., Ku S., Meagher A., O’Conner T., Ward R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology, 122: 1376-1387, 2002.[Medline]
  22. Konishi M., Kikuchi-Yanoshita R., Tanaka K., Muraoka M., Onda A., Okumura Y., Kishi N., Iwama T., Mori T., Koike M., Ushio K., Chiba M., Nomizu S., Konishi F., Utsunomiya J., Miyaki M. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology, 111: 307-317, 1996.[Medline]
  23. Kambara T., Matsubara N., Nakagawa H., Notohar K., Nagasaka T., Yoshino T., Isozaki H., Sharp G. B., Shimizu K., Jass J. R., Tanaka N. High frequency of low-level microsatellite instability in early colorectal cancer. Cancer Res., 61: 7743-7746, 2001.[Abstract/Free Full Text]
  24. Chan I. O-O., Broaddus R. R., Houlihan P. S., Issa J-P., Hamilton S. R., Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am. J. Pathol., 160: 1823-1830, 2002.[Abstract/Free Full Text]
  25. Hawkins N. J., Ward R. L. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J. Natl. Cancer Inst., 93: 1307-1313, 2001.[Abstract/Free Full Text]
  26. Sawyer E. J., Cerar A., Hanby A. M., Gorman P., Arends M., Talbot I. C., Tomlinson I. P. Molecular characteristics of serrated adenomas of the colorectum. Gut, 51: 200-206, 2002.[Abstract/Free Full Text]
  27. Biemer-Huttmann A-E., Walsh M. D., McGuckin M. A., Simms L. A., Young J., Leggett B. A., Jass J. R. Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. Clin. Cancer Res., 6: 1909-1916, 2000.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Mol. Diagn.Home page
A. R. Sepulveda, D. Jones, S. Ogino, W. Samowitz, M. L. Gulley, R. Edwards, V. Levenson, V. M. Pratt, B. Yang, K. Nafa, et al.
CpG Methylation Analysis--Current Status of Clinical Assays and Potential Applications in Molecular Diagnostics: A Report of the Association for Molecular Pathology
J. Mol. Diagn., July 1, 2009; 11(4): 266 - 278.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S. Ogino, K. Nosho, G. J Kirkner, T. Kawasaki, J. A Meyerhardt, M. Loda, E. L Giovannucci, and C. S Fuchs
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Gut, January 1, 2009; 58(1): 90 - 96.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
S. Ogino and A. Goel
Molecular Classification and Correlates in Colorectal Cancer
J. Mol. Diagn., January 1, 2008; 10(1): 13 - 27.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S. Ogino, T. Kawasaki, G. J Kirkner, Y. Suemoto, J. A Meyerhardt, and C. S Fuchs
Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer
Gut, November 1, 2007; 56(11): 1564 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Ogino, A. Hazra, G. J. Tranah, G. J. Kirkner, T. Kawasaki, K. Nosho, M. Ohnishi, Y. Suemoto, J. A. Meyerhardt, D. J. Hunter, et al.
MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer
Carcinogenesis, September 1, 2007; 28(9): 1985 - 1990.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. A. Newcomb, Y. Zheng, V. M. Chia, L. M. Morimoto, V. P. Doria-Rose, A. Templeton, S. N. Thibodeau, and J. D. Potter
Estrogen Plus Progestin Use, Microsatellite Instability, and the Risk of Colorectal Cancer in Women
Cancer Res., August 1, 2007; 67(15): 7534 - 7539.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Wallner, A. Herbst, A. Behrens, A. Crispin, P. Stieber, B. Goke, R. Lamerz, and F. T. Kolligs
Methylation of Serum DNA Is an Independent Prognostic Marker in Colorectal Cancer
Clin. Cancer Res., December 15, 2006; 12(24): 7347 - 7352.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Young and J. R. Jass
The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature.
Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1778 - 1784.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
P Minoo, K Baker, R Goswami, G Chong, W D Foulkes, A R Ruszkiewicz, M Barker, D Buchanan, J Young, and J R Jass
Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis
Gut, October 1, 2006; 55(10): 1467 - 1474.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
K. M. Murphy, S. Zhang, T. Geiger, M. J. Hafez, J. Bacher, K. D. Berg, and J. R. Eshleman
Comparison of the Microsatellite Instability Analysis System and the Bethesda Panel for the Determination of Microsatellite Instability in Colorectal Cancers
J. Mol. Diagn., July 1, 2006; 8(3): 305 - 311.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S Ogino, M Cantor, T Kawasaki, M Brahmandam, G J Kirkner, D J Weisenberger, M Campan, P W Laird, M Loda, and C S Fuchs
CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies
Gut, July 1, 2006; 55(7): 1000 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C M Wright, O F Dent, R C Newland, M Barker, P H Chapuis, E L Bokey, J P Young, B A Leggett, J R Jass, and G A Macdonald
Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma
Gut, January 1, 2005; 54(1): 103 - 108.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Nagasaka, H. Sasamoto, K. Notohara, H. M. Cullings, M. Takeda, K. Kimura, T. Kambara, D. G. MacPhee, J. Young, B. A. Leggett, et al.
Colorectal Cancer With Mutation in BRAF, KRAS, and Wild-Type With Respect to Both Oncogenes Showing Different Patterns of DNA Methylation
J. Clin. Oncol., November 15, 2004; 22(22): 4584 - 4594.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K Baker, Y Zhang, C Jin, and J R Jass
Proximal versus distal hyperplastic polyps of the colorectum: different lesions or a biological spectrum?
J. Clin. Pathol., October 1, 2004; 57(10): 1089 - 1093.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
T Kambara, L A Simms, V L J Whitehall, K J Spring, C V A Wynter, M D Walsh, M A Barker, S Arnold, A McGivern, N Matsubara, et al.
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
Gut, August 1, 2004; 53(8): 1137 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
T Higuchi and J R Jass
My approach to serrated polyps of the colorectum
J. Clin. Pathol., July 1, 2004; 57(7): 682 - 686.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C V A Wynter, M D Walsh, T Higuchi, B A Leggett, J Young, and J R Jass
Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer
Gut, April 1, 2004; 53(4): 573 - 580.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. L. Ward, K. Cheong, S.-L. Ku, A. Meagher, T. O'Connor, and N. J. Hawkins
Adverse Prognostic Effect of Methylation in Colorectal Cancer Is Reversed by Microsatellite Instability
J. Clin. Oncol., October 15, 2003; 21(20): 3729 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G.M. Nash, M. Gimbel, J. Shia, A.T. Culliford, D.R. Nathanson, M. Ndubuisi, Y. Yamaguchi, Z.S. Zeng, F. Barany, and P.B. Paty
Automated, Multiplex Assay for High-Frequency Microsatellite Instability in Colorectal Cancer
J. Clin. Oncol., August 15, 2003; 21(16): 3105 - 3112.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-P. J. Issa
Methylation and Prognosis: Of Molecular Clocks and Hypermethylator Phenotypes
Clin. Cancer Res., August 1, 2003; 9(8): 2879 - 2881.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. R. Jass
Serrated Adenoma of the Colorectum: A Lesion with Teeth
Am. J. Pathol., March 1, 2003; 162(3): 705 - 708.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitehall, V. L. J.
Right arrow Articles by Jass, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitehall, V. L. J.
Right arrow Articles by Jass, J. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online